Table 1.
Key Characteristics of Face-to-Face and Telemedicine HIV Patients
| F2F | TM | |
|---|---|---|
| Gender | No. (%) | No. (%) |
| Females | 106 (53.0) | 90 (48.6) |
| Males | 89 (44.5) | 95 (51.4) |
| Transgender | 5 (2.5) | 0 (0) |
| 200 (100) | 185 (100) | |
| Race | ||
| Black | 164 (82.0) | 152 (82.2) |
| White | 30 (15.0) | 32 (17.3) |
| Others | 6 (3.0) | 1 (0.5) |
| 200 (100) | 185 (100) | |
| Age | ||
| 18–30 y | 21 (10.5) | 18 (9.7) |
| 31–50 y | 77 (38.5) | 68 (36.8) |
| 51+ y | 102 (51.0) | 99 (53.5) |
| 200 (100) | 185 (100) | |
| Medication change code | ||
| 0 = no change | 162 (81) | 158 (85.4) |
| 1 = new therapy/physician preference | 19 (9.5) | 5 (2.7) |
| 2 = failure of therapy | 8 (4) | 4 (2.2) |
| 3 = adverse effect | 10 (5) | 10 (5.4) |
| 4 = consolidation for pill burden | 1 (0.5) | 8 (4.3) |
| Resistance code | ||
| No new resistance | 192 (96) | 183 (98.9) |
| New resistance | 8 (4) | 2 (1.1) |
| Comorbidities | ||
| Cardiac | 117 (58.5) | 55 (29.7) |
| Respiratory | 17 (8.5) | 3 (1.6) |
| Diabetes | 26 (13) | 20 (10.8) |
| Chronic kidney disease (stage 3–5) | 63 (31.5) | 33 (17.8) |
| Neuropsychiatry | 75 (37.5) | 32 (17.3) |
| Liver disease | 17 (8.5) | 12 (6.5) |
| Dental | 11 (5.5) | 4 (2.2) |
| Alcoholism | 7 (3.5) | 5 (2.7) |
| Drug abuse | 16 (8) | 7 (3.8) |
| Cancer | 1 (0.5) | 4 (2.2) |
| Autoimmune diseases | 2 (1) | 3 (1.6) |
Abbreviations: F2F, face-to-face; TM, telemedicine.